{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:44:47Z","timestamp":1779345887065,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd011272.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000}}],"reference-count":254,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011272.pub3","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:31:27Z","timestamp":1689075087000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rapamycin and rapalogs for tuberous sclerosis complex"],"prefix":"10.1002","volume":"2023","author":[{"given":"Teguh Haryo","family":"Sasongko","sequence":"additional","affiliation":[{"name":"Department of Physiology; School of Medicine, International Medical University; Kuala Lumpur Malaysia"},{"name":"Institute for Research, Development, and Innovation, International Medical University; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaraswamy","family":"Kademane","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; Arunai Medical College and Hospital; Tiruvannamalai, Tamilnadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Chai Soon Hou","sequence":"additional","affiliation":[{"name":"Perdana University - Royal College of Surgeons in Ireland (RCSI) School of Medicine; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan Xin Yi","family":"Jocelyn","sequence":"additional","affiliation":[{"name":"Perdana University - Royal College of Surgeons in Ireland (RCSI) School of Medicine; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZAMH","family":"Zabidi-Hussin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Cyberjaya; Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011272.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1200\/jco.2012.30.15_suppl.4632","article-title":"Updated safety results from EXIST-2: everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM)","volume":"30","author":"Bissler","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011272.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/j.juro.2014.02.1508","article-title":"Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex: exist-2 long-term efficacy and safety","volume":"191","author":"Bissler","year":"2014","journal-title":"Journal of Urology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011272.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/j.juro.2012.02.1636","article-title":"Exist-2: effect of everolimus on angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis","volume":"187","author":"Bissler","year":"2012","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","article-title":"Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2","volume":"34","author":"Bissler","year":"2019","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0005|cit5","first-page":"7","article-title":"Examining everolimus in a study of tuberous sclerosis complex (TSC) trial (EXIST-2): updated safety results","volume":"110","author":"Bissler","year":"2012","journal-title":"BJU International"},{"issue":"8","key":"10.1002\/14651858.CD011272.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PloS one"},{"issue":"9869","key":"10.1002\/14651858.CD011272.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1569-9056(15)60004-5","article-title":"Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) from EXIST-2: continued efficacy and diminishing adverse events after ~3.5 years of treatment","volume":"14","author":"Bissler","year":"2015","journal-title":"European Urology Supplements"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1016\/S1569-9056(14)61119-2","article-title":"Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC): EXIST-2 3-year follow-up","volume":"13","author":"Bissler","year":"2014","journal-title":"European Urology Supplements"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011272.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/jco.2012.30.5_suppl.356","article-title":"Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2","volume":"30","author":"Bissler","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"e0201005","DOI":"10.1371\/journal.pone.0201005","article-title":"Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis","volume":"13","author":"Bissler","year":"2018","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1093\/ndt\/gft158","article-title":"Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM): exist-2 update","volume":"28","author":"Bissler","year":"2013","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD011272.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","article-title":"Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies","volume":"32","author":"Franz","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/bju.12941\/abstract","article-title":"Effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis complex (TSC) being treated for subependymal giant cell astrocytoma (SEGA)","volume":"114","author":"Franz","year":"2014","journal-title":"BJU International"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/ejhg.2015.47","article-title":"Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2","volume":"23","author":"Kwiatkowski","year":"2015","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0017|cit17","unstructured":"Efficacy and safety of RAD001 in patients aged 18 and over with Angiomyolipoma associated with either tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM) (EXIST-2) clinicaltrials.gov\/ct2\/show\/NCT00790400"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","article-title":"Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.","volume":"34","author":"Bissler","year":"2019","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00467-017-3806-1","article-title":"The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma","volume":"33","author":"Bissler","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"1 Meeting Abstr","key":"10.1002\/14651858.CD011272.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"P04.188","DOI":"10.1212\/WNL.78.1","article-title":"Everolimus for the treatment of renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma","volume":"78","author":"Franz","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"P2.235","DOI":"10.1212\/WNL.84.14_supplement.P2.235","article-title":"Long-term efficacy and safety of everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in exist-1: approximately 3.5 years of exposure","volume":"84","author":"Franz","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Franz D Lam D Cauwel H Jozwiak S Effect of everolimus on subependymal nodules (SENs) and tubers in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Results from the exist-1 trial 65th American Academy of Neurology Annual Meeting San Diego, CA United States Lippincott Williams and Wilkins 2013","DOI":"10.1212\/WNL.80.7_supplement.P01.049"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD011272.pub3-BIB0023|cit23","first-page":"P01.049","article-title":"Effect of everolimus on subependymal nodules (SENs) and tubers in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): results from the exist-1 trial","volume":"80","author":"Franz","year":"2013","journal-title":"Neurology"},{"issue":"9861","key":"10.1002\/14651858.CD011272.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/ana.24498","article-title":"Everolimus for subependymal giant cell astrocytoma associated with tuberous sclerosis complex: final 4-year long-term results from EXIST-1","volume":"78","author":"Franz","year":"2015","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1002\/ana.24477","article-title":"Everolimus for subependymal giant cell astrocytoma associated with tuberous sclerosis complex: final long-term results from approximately 4 years of treatment in EXIST-1","volume":"78","author":"Franz","year":"2015","journal-title":"Annals of Neurology"},{"issue":"13","key":"10.1002\/14651858.CD011272.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet. Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0029|cit29","first-page":"704","article-title":"Effect of everolimus on skin lesions in patients being treated for subependymal giant cell astrocytoma: final 4-year results from EXIST-1","volume":"33","author":"Franz","year":"2016","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1002\/ana.24226","article-title":"Safety of everolimus by age category for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): results from the exist-1 trial","volume":"76","author":"Franz","year":"2014","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD011272.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","article-title":"Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies","volume":"32","author":"Franz","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/bju.12941\/abstract","article-title":"Effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis complex (TSC) being treated for subependymal giant cell astrocytoma (SEGA)","volume":"114","author":"Franz","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1002\/ana.24477","article-title":"The effect of everolimus on growth and sexual maturation in patients treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex: results from the 4-year final analysis of EXIST-1","volume":"78","author":"Franz","year":"2015","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"ii325","DOI":"10.1093\/ndt\/gfs232","article-title":"Effect of everolimus therapy on renal angiomyolipoma response in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: exploratory results from EXIST-1","volume":"27","author":"Jansen","year":"2012","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S1569-9056(12)60073-6","article-title":"The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma","volume":"11","author":"J\u00f3\u017awiak","year":"2012","journal-title":"European Urology, Supplements"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1469-8749.2012.04283.x","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): the EXIST-1 trial","volume":"54","author":"J\u00f3\u017awiak","year":"2012","journal-title":"Developmental Medicine and Child Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S1090-3798%2813%2970150-8","article-title":"Everolimus for subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): results from the EXIST-1 trial by age category","volume":"17","author":"J\u00f3\u017awiak","year":"2013","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S1090-3798%2813%2970418-5","article-title":"Safety of everolimus by age category for subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): results from the EXIST-1 trial","volume":"17","author":"J\u00f3\u017awiak","year":"2013","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpeds.2016.01.027","article-title":"Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial","volume":"172","author":"J\u00f3\u017awiak","year":"2016","journal-title":"Journal of Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon.12.146","article-title":"Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"8","author":"J\u00f3\u017awiak","year":"2012","journal-title":"Future Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4274\/tnd.78466","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis: a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Karao\u011flan","year":"2018","journal-title":"Frontiers in Neurology \/ N\u00f6rolojide \u00d6ne \u00c7\u0131kanlar, Turk noroloji dergisi [turkish journal of neurology]"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00467-015-3158-7","article-title":"Effect of everolimus on renal angiomyolipoma in pediatric patients from the final analysis of exist-1","volume":"30","author":"Kingswood","year":"2015","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"i316","DOI":"10.1093\/ndt\/gft126","article-title":"Effect of everolimus on renal angiomyolipoma (AML) in patients with tuberous sclerosis complex (TSC) being treated for subependymal giant cell astrocytoma (SEGA)","volume":"28","author":"Kingswood","year":"2013","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"i316","DOI":"10.1093\/ndt\/gft126","article-title":"Pharmacokinetics and exposure-safety relationship of everolimus in patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis","volume":"28","author":"Kingswood","year":"2013","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","article-title":"The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","article-title":"The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/ejhg.2015.47","article-title":"Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2","volume":"23","author":"Kwiatkowski","year":"2015","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0048|cit48","unstructured":"Efficacy and safety of Everolimus (RAD001) in patients of all ages with subependymal giant cell astrocytoma associated with tuberous sclerosis complex (TSC)(EXIST-1) www.clinicaltrials.gov\/ct2\/show\/NCT00789828"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011272.pub3-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor152","article-title":"Everolimus treatment f subpendymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): the EXIST-1 trial","volume":"13","author":"Sparagana","year":"2011","journal-title":"Neuro-Oncology"},{"issue":"S19","key":"10.1002\/14651858.CD011272.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1002\/ana.24477","article-title":"Everolimus exposure and overall tolerabilityin patients treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex: results from the 4-year final analysis of EXIST-1","volume":"78","author":"Sparagana","year":"2015","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet. Child & Adolescent Health"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/jir.12324","article-title":"Adjunctive everolimus therapy for the treatment of refractory seizures in people with tuberous sclerosis complex","volume":"60","author":"De Vries","year":"2016","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1002\/ana.25022","article-title":"Psychometric evaluation of quality of life in a three-arm, randomized, double-blind, placebo-controlled phase 3 study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3)","volume":"82","author":"Franz","year":"2017","journal-title":"Annals of Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011272.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S9.007","DOI":"10.1212\/WNL.90.15_supplement.S9.007","article-title":"Efficacy and safety of everolimus based on prior and concomitant antiepileptic drugs in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures: a subanalysis of the phase 3 EXIST-3 study","volume":"90","author":"Franz","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ene.13091","article-title":"Exposure-response analysis of adjunctive everolimus therapy in patients with refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)","volume":"23","author":"French","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1111\/epi.13944","article-title":"Adjunctive everolimus in patients with treatment-refractory seizures associated with tuberous sclerosis complex (TSC): analysis of exposure-efficacy and exposure-safety relationships in the randomized, phase 3, exist-3 trial","volume":"58","author":"French","year":"2017","journal-title":"Epilepsia"},{"issue":"10056","key":"10.1002\/14651858.CD011272.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2017.08.293","article-title":"Outcomes in patients with tuberous sclerosis complex-associated treatment-refractory seizures, transitioning from placebo in core phase to everolimus during extension phase of the EXIST-3 trial","volume":"381","author":"French","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1002\/ana.24759","article-title":"Adjunctive everolimus therapy for the treatment of refractory seizures associated with tuberous sclerosis complex: results from a randomized, placebo-controlled, phase 3 trial","volume":"80","author":"French","year":"2016","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex","volume":"52","author":"Goyer","year":"2015","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","article-title":"Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan","volume":"41","author":"Mizuguchi","year":"2019","journal-title":"Brain & Development"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0062|cit62","first-page":"S283","article-title":"Efficacy and safety of everolimus in Japanese patients with refractory seizures associated with TSC","volume":"49","author":"Mizuguchi","year":"2017","journal-title":"No to hattatsu [Brain and development]"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0063|cit63","unstructured":"A placebo-controlled study of efficacy & safety of 2 trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) & refractory partial-onset seizures clinicaltrials.gov\/ct2\/show\/record\/NCT01713946"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1111\/epi.13944","article-title":"Impact of everolimus treatment on quality of life (QOL) in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures in the context of an interventional clinical trial (EXIST-3)","volume":"58","author":"Nabbout","year":"2017","journal-title":"Epilepsia"},{"issue":"S3","key":"10.1002\/14651858.CD011272.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1111\/epi.14612","article-title":"Long-term efficacy and safety of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures: final analysis of the exist-3 study","volume":"59","author":"Polster","year":"2018","journal-title":"Epilepsia"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD011272.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"P3.146","DOI":"10.1212\/WNL.88.16_supplement.P3.146","article-title":"Efficacy and safety of adjunctive everolimus for treatment resistant focal-onset seizures in tuberous sclerosis according to age: insights from EXIST-3","volume":"88","author":"Roberts","year":"2017","journal-title":"American Academy of Neurology"},{"issue":"S3","key":"10.1002\/14651858.CD011272.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/epi.14612","article-title":"Outcomes among adult patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures treated with adjunctive everolimus: final analysis of the exist-3 study","volume":"59","author":"Wiemer-Kruel","year":"2018","journal-title":"Epilepsia"},{"issue":"S3","key":"10.1002\/14651858.CD011272.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1111\/epi.14612","article-title":"Long-term safety, rollover study of adjunctive everolimus in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures who continue to benefit from everolimus treatment after completion of exist-3","volume":"59","author":"Yapici","year":"2018","journal-title":"Epilepsia"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD011272.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"P2.057","DOI":"10.1212\/WNL.88.16_supplement.P2.057","article-title":"Psychometric evaluation of quality of life measures in a three-arm, randomized, double-blind, placebo-controlled phase III study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3)","volume":"88","author":"Vries","year":"2017","journal-title":"American Academy of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3389\/fphar.2018.00964","article-title":"Measuring health-related quality of life in tuberous sclerosis complex - psychometric evaluation of three instruments in individuals with refractory epilepsy","volume":"9","author":"Vries","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs in R&D"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0072|cit72","unstructured":"Topical rapamycin therapy to alleviate cutaneous manifestations of tuberous sclerosis complex (TSC) and neurofibromatosis I (NF1) clinicaltrials.gov\/ct2\/show\/NCT01031901"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0074|cit74","unstructured":"Topical rapamycin to erase angiofibromas in TSC clinicaltrials.gov\/ct2\/show\/record\/NCT01526356"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0076|cit76","unstructured":"Trial of RAD001 and neurocognition in tuberous sclerosis complex (TSC) clinicaltrials.gov\/ct2\/show\/record\/NCT01289912"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0077|cit77","unstructured":"Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-022655-29-NL"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0078|cit78","unstructured":"Study into treatment of children with difficult to treat epilepsy due to Tuberous sclerosis complex with rapamycin trialsearch.who.int\/Trial2.aspx?TrialID=NTR3178"},{"issue":"10","key":"10.1002\/14651858.CD011272.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0080|cit80","unstructured":"Efficacy of RAD001\/everolimus in autism and neuropsychological deficits in children with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT01730209"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1212\/WNL.0000000000007749","article-title":"A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex","volume":"93","author":"Overwater","year":"2019","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0082|cit82","unstructured":"Randomized, double-blind, placebo-controlled, clinical trial with OSD-001 for skin lesions due to tuberous sclerosis complex upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000014541"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA dermatology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0084|cit84","unstructured":"Phase III trial of topical formulation of sirolimus to skin lesions in patients with tuberous sclerosis complex (TSC) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02635789"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.jid.2018.03.1067","article-title":"Sirolimus gel treatment for tuberous sclerosis complex involving facial angiofibromas and cephalic plaques: a multicenter randomized controlled trial","volume":"138","author":"Wataya-Kaneda","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","article-title":"Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial","volume":"154","author":"Wataya-Kaneda","year":"2018","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3171\/2010.7.PEDS10221","article-title":"Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex","volume":"6","author":"Birca","year":"2010","journal-title":"Journal of Neurosurgery. Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","article-title":"Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2","volume":"34","author":"Bissler","journal-title":"Nephrology, Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0089|cit89","first-page":"292","article-title":"Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis","volume":"31","author":"Cabrera Lopez","year":"2011","journal-title":"Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0090|cit90","unstructured":"Efficacy of everolimus for TSC-associated renal angiomyolipoma www.chictr.org.cn\/showprojen.aspx?proj=9856"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0091|cit91","unstructured":"TSC1\/2 gene detection and everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex www.chictr.org.cn\/showprojen.aspx?proj=13935"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Cuevas Asencio I Albornoz Lapez R Salido Vallejo R Reyes Malia M Topical sirolimus 0.4% formulation for treatment of facial angiofibromas Farmacia Hospitalaria 2012 36 5 433 4 10.1016\/j.farma.2011.09.006 22858090","DOI":"10.1016\/j.farma.2011.09.006"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0096|cit96","unstructured":"EMINENTS (Everolimus MaINtEnNance Therapy in SEGA) www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005584"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0097|cit97","unstructured":"Clinical trial to determine the efficacy and safety of rapamycin in angiomyolipomas in patients with tuberous sclerosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-005978-30-ES"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0098|cit98","unstructured":"The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-022583-13-DE"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australasian Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurology. Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1802066","DOI":"10.1183\/13993003.02066-2018","article-title":"Analysis of the MILES cohort reveals determinants of disease progression and\u00c2 treatment response in lymphangioleiomyomatosis","volume":"53","author":"Gupta","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2006.07.017","article-title":"Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex","volume":"18","author":"Herry","year":"2007","journal-title":"European Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis","volume":"159","author":"Hofbauer","year":"2008","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0105|cit105","unstructured":"Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000003457"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0106|cit106","unstructured":"Clinical trial for development of topical rapamycin treatment for white macules due to tuberous sclerosis complex, vitiligo vulgaris, and other congenital diseases upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000007206"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0107|cit107","unstructured":"Therapeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000013524"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0108|cit108","unstructured":"Clinical study of safety and efficacy of rapamycin topical medication for skin lesions due to tuberous sclerosis complex upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000017546"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0109|cit109","unstructured":"Study of everolimus for autistic spectrum disorder in tuberous sclerosis upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000027932"},{"issue":"20","key":"10.1002\/14651858.CD011272.pub3-BIB0110|cit110","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD011272.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0883073808321764","article-title":"Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex","volume":"23","author":"Koenig","year":"2008","journal-title":"Journal of Child Neurology"},{"issue":"19","key":"10.1002\/14651858.CD011272.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011272.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/WNL.0b013e318248a232","article-title":"New therapies for tuber-less sclerosis: White matter matters?","volume":"78","author":"Ess","year":"2012","journal-title":"American Academy of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0115|cit115","unstructured":"Everolimus (RAD001 therapy of giant cell astrocytomas in patients with tuberous sclerosis complex www.clinicaltrials.gov\/ct2\/show\/NCT00411619"},{"issue":"8","key":"10.1002\/14651858.CD011272.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e318247ca8d","article-title":"Everolimus alters white matter diffusion in tuberous sclerosis complex","volume":"78","author":"Tillema","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0118|cit118","unstructured":"Everolimus (RAD001) therapy for epilepsy in patients with tuberous sclerosis complex (TSC) clinicaltrials.gov\/ct2\/show\/record\/NCT01070316 NA"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/pbc.22298","article-title":"Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors","volume":"54","author":"Lam","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0120|cit120","unstructured":"Study of the disease process of lymphangioleiomyomatosis clinicaltrials.gov\/ct2\/show\/NCT00001465"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0121|cit121","unstructured":"Role of genetic factors in the development of lung disease clinicaltrials.gov\/ct2\/show\/NCT00001532"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0122|cit122","unstructured":"Study of skin tumors in tuberous sclerosis clinicaltrials.gov\/ct2\/show\/NCT00001975"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0123|cit123","unstructured":"Rapamycin therapy for patients with tuberous sclerosis complex and sporadic LAM clinicaltrials.gov\/ct2\/show\/NCT00457808"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0124|cit124","unstructured":"RAD001 therapy of angiomyolipomata in patients with TS complex and sporadic LAM clinicaltrials.gov\/ct2\/show\/NCT00457964"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0125|cit125","unstructured":"Trial of efficacy and safety of sirolimus in tuberous sclerosis and LAM clinicaltrials.gov\/ct2\/show\/NCT00490789"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0126|cit126","unstructured":"Effect of fasting on the size of abdominal lymphatic tumors in women clinicaltrials.gov\/ct2\/show\/NCT00552955"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0127|cit127","unstructured":"Long term follow up for RAD001 therapy of angiomyolipomata in patients with tuberous sclerosis (TSC) and sporadic lymphangioleiomyomatosis (LAM) clinicaltrials.gov\/ct2\/show\/NCT00792766"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0128|cit128","unstructured":"Studies of autistic patients: gene networks and clinical subtypes clinicaltrials.gov\/ct2\/show\/NCT01092208"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0129|cit129","unstructured":"Rapamycin in angiomyolipomas in patients with tuberous sclerosis clinicaltrials.gov\/ct2\/show\/NCT01217125"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0130|cit130","unstructured":"Sabril for complex partial seizures in adult tolerability study (TS) patients clinicaltrials.gov\/ct2\/show\/NCT01266291"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0131|cit131","unstructured":"Potential EEG biomarkers and antiepileptogenic strategies for epilepsy in TSC clinicaltrials.gov\/ct2\/show\/NCT01767779"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0132|cit132","unstructured":"Early biomarkers of autism in infants with tuberous sclerosis complex (TSC) clinicaltrials.gov\/ct2\/show\/NCT01780441"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0133|cit133","unstructured":"Rapalogues for autism phenotype in TSC: a feasibility study clinicaltrials.gov\/ct2\/show\/NCT01929642"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0134|cit134","unstructured":"Treatment of renal angiomyolipomas in tuberous sclerosis by beta-blockers clinicaltrials.gov\/ct2\/show\/NCT02104011"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0135|cit135","unstructured":"Everolimus for cancer with TSC1 or TSC2 mutation clinicaltrials.gov\/ct2\/show\/NCT02201212"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0136|cit136","unstructured":"Characterization of patients with tuberous sclerosis complex, lymphangioleiomyomatosis and angiomyolipoma clinicaltrials.gov\/ct2\/show\/NCT02325505"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0137|cit137","unstructured":"A pilot study to evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in TSC and FCD clinicaltrials.gov\/ct2\/show\/NCT02451696"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0138|cit138","unstructured":"Autism spectrum disorder (ASD) and intellectual disability (ID) determinants in tuberous sclerosis complex (TSC) clinicaltrials.gov\/ct2\/show\/NCT02461459"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0139|cit139","unstructured":"Long-term trial of topical sirolimus to angiofibroma in patient with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT02634931"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0140|cit140","unstructured":"Biomarkers for tuberous sclerosis complex (BioTuScCom) clinicaltrials.gov\/ct2\/show\/NCT02654340"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0141|cit141","unstructured":"Sapanisertib in treating patients with locally advanced or metastatic bladder cancer with TSC1 and\/or TSC2 mutations clinicaltrials.gov\/ct2\/show\/NCT03047213"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0142|cit142","unstructured":"PI3K\/mTOR inhibitor LY3023414 in treating patients with relapsed or refractory advanced solid tumors, non-hodgkin lymphoma, or histiocytic disorders with TSC or PI3K\/MTOR mutations (a pediatric MATCH treatment trial) clinicaltrials.gov\/ct2\/show\/NCT03213678"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0143|cit143","unstructured":"Safety and efficacy of everolimus (Afinitor\u00ae) in Chinese adult patients with angiomyolipoma associated with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT03525834"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0144|cit144","unstructured":"Multi-center clinical study on the diagnosis and treatment management of rare neurological disease in children clinicaltrials.gov\/ct2\/show\/NCT03649919"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/pbc.22401","article-title":"Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex","volume":"54","author":"Pressey","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"issue":"10","key":"10.1002\/14651858.CD011272.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1007\/s10928-013-9308-2","article-title":"Population PK-PD modeling of everolimusin the treatment of patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytomas (SEGA)","volume":"40","author":"Sallas","year":"2013","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pediatrneurol.2010.01.016","article-title":"Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus","volume":"42","author":"Sparagana","year":"2010","journal-title":"Pediatric Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11255-012-0292-z","article-title":"Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis","volume":"44","author":"Staehler","year":"2012","journal-title":"International Urology and Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","article-title":"A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity","volume":"165","author":"Wataya-Kaneda","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Archives of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","article-title":"Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex","volume":"151","author":"Wataya-Kaneda","year":"2015","journal-title":"JAMA Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"28","author":"Wheless","year":"2013","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2006.05.018","article-title":"Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex","volume":"48","author":"Wienecke","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00381-010-1222-y","article-title":"Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex","volume":"27","author":"Yalon","year":"2011","journal-title":"Child's Nervous System"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2213-2600(13)70098-5","article-title":"A biomarker for lymphangioleiomyomatosis","volume":"1","author":"Kwiatkowski","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"A1100","DOI":"10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A1100","article-title":"Serum levels of vegf-c are elevated in sporadic but not tuberous sclerosis associated-lam, correlate with the need for supplemental oxygen, and impact lung function response to sirolimus","volume":"197","author":"Wu","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"A6351","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6351","article-title":"Baseline serum VEGF-D levels are associated with disease severity and treatment response in lymphangioleiomyomatosis","volume":"183","author":"Young","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.seizure.2018.08.023","article-title":"The importance of the study of brain calcifications in patients with tuberous sclerosis complex","volume":"61","author":"Fonseca dos Santos-Junior","year":"2018","journal-title":"Seizure - European Journal of Epilepsy"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2018.06.011","article-title":"Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis","volume":"60","author":"Zhang","year":"2018","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0163|cit163","unstructured":"Topical Rapamycin and calcitriol for angiofibroma of tuberous sclerosis clinicaltrials.gov\/ct2\/show\/NCT03140449"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0164|cit164","unstructured":"A study of everolimus in the treatment of neurocognitive problems in tuberous sclerosis clinicaltrials.gov\/ct2\/show\/NCT01954693 10.1186\/ISRCTN09739757"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13063-016-1446-6","article-title":"The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial","volume":"17","author":"Randell","year":"2016","journal-title":"Trials"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0166|cit166","unstructured":"Clinical trial in patients with tuberous sclerosis for the study of the effects of topical rapamycin in reducing facial tumors associated with the disease trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-006308-12-ES"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0167|cit167","unstructured":"Topical everolimus in patients with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT02860494"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0168|cit168","unstructured":"Topical sirolimus ointment for cutaneous angiofibromas in subjects with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT03363763"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0169|cit169","unstructured":"Dose-ranging efficacy and safety study of topical rapamycin cream for facial angiofibroma associated with tuberous sclerosis complex clinicaltrials.gov\/ct2\/show\/NCT03826628 NA https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03826628?id=NCT03826628&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3389\/fneur.2019.01116","article-title":"Tuberous sclerosis complex (TSC): expert recommendations for provision of coordinated care","volume":"10","author":"Annear","year":"2019","journal-title":"Frontiers in Neurology"},{"issue":"1-4","key":"10.1002\/14651858.CD011272.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"Journal of Chemical Biology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The two TORCs and Akt","volume":"12","author":"Bhaskar","year":"2007","journal-title":"Developmental Cell"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ceb.2008.12.011","article-title":"PI3K and mTOR inhibitors: a new generation of targeted anticancer agents","volume":"21","author":"Brachmann","year":"2009","journal-title":"Current Opinion in Cell Biology"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00381-013-2185-6","article-title":"Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86","volume":"30","author":"Canpolat","year":"2014","journal-title":"Child's Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004390000348","article-title":"Molecular genetic advances in tuberous sclerosis","volume":"107","author":"Cheadle","year":"2000","journal-title":"Human Genetics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0179|cit179","unstructured":"Common terminology criteria for adverse events (CTCAE) National Cancer Institute Cancer Therapy Evaluation Program 2006"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mTOR) in tuberoussclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2015","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"American Journal of Human Genetics"},{"issue":"19","key":"10.1002\/14651858.CD011272.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1866-1955-6-10","article-title":"Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers","volume":"6","author":"Eden","year":"2014","journal-title":"Journal of Neurodevelopmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molmed.2010.10.002","article-title":"Rapamycin for treating tuberous sclerosis and autism spectrum disorders","volume":"17","author":"Ehninger","year":"2011","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials:methodological issues","volume":"30","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD011272.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0189|cit189","unstructured":"Falotico R Are all sirolimus analogs alike? Angioplasty Summit; TCT Asia Pacific; 2005 Apr 28; Seoul, Korea 2005"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijdevneu.2013.02.008","article-title":"A circuitry and biochemical basis for tuberoussclerosis symptoms: from epilepsy to neurocognitive deficits","volume":"31","author":"Feliciano","year":"2013","journal-title":"International Journal of Developmental Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD011272.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1101\/gad.901101","article-title":"TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth","volume":"15","author":"Gao","year":"2001","journal-title":"Genes & Development"},{"issue":"34","key":"10.1002\/14651858.CD011272.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova","year":"2002","journal-title":"Journal of Biological Chemistry"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Archives of Dermatology"},{"issue":"7417","key":"10.1002\/14651858.CD011272.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0195|cit195","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0196|cit196","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"e001493","DOI":"10.1161\/JAHA.114.001493","article-title":"Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group","volume":"3","author":"Hinton","year":"2014","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/humu.22007","article-title":"Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex","volume":"33","author":"Hoogeveen-Westerveld","year":"2012","journal-title":"Human Mutation"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.22202","article-title":"Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex","volume":"34","author":"Hoogeveen-Westerveld","year":"2013","journal-title":"Human Mutation"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","article-title":"National Institutes of Health consensus conference: tuberous sclerosis complex","volume":"57","author":"Hyman","year":"2000","journal-title":"Archives of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.00076209","article-title":"European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis","volume":"35","author":"Johnson","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1017\/S0033291702007092","article-title":"Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex","volume":"33","author":"Joinson","year":"2003","journal-title":"Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","article-title":"A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells","volume":"11","author":"Kwiatkowski","year":"2002","journal-title":"Human Molecular Genetics"},{"issue":"Pt 1","key":"10.1002\/14651858.CD011272.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1469-1809.2003.00012.x","article-title":"Tuberous sclerosis: from tubers to mTOR","volume":"67","author":"Kwiatkowski","year":"2003","journal-title":"Annals of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD011272.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","article-title":"Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Pharmacology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0209|cit209","unstructured":"Lefebvre C Manheimer E Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook of Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0210|cit210","unstructured":"Povey S Ekong R Tuberous sclerosis database: Tuberous sclerosis 1 (TSC1) chromium.liacs.nl\/LOVD2\/TSC\/home.php?select_db=TSC1"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0211|cit211","unstructured":"Povey S Ekong R Tuberous sclerosis database: Tuberous sclerosis 2 (TSC2) chromium.liacs.nl\/LOVD2\/TSC\/home.php?select_db=TSC2"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/2229-5178.105488","article-title":"Topical rapamycin (sirolimus) for facial angiofibromas","volume":"4","author":"Madke","year":"2013","journal-title":"Indian Dermatology Online Journal"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0214|cit214","volume-title":"Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics","author":"McCormack","year":"2010"},{"issue":"45","key":"10.1002\/14651858.CD011272.pub3-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"15704","DOI":"10.1523\/JNEUROSCI.2392-12.2012","article-title":"Impaired autophagy in neurons after disinhibition of mammalian target ofrapamycin and its contribution to epileptogenesis","volume":"32","author":"McMahon","year":"2012","journal-title":"Journal of Neuroscience"},{"issue":"21","key":"10.1002\/14651858.CD011272.pub3-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target ofrapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead toimproved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis","volume":"165","author":"Mutizwa","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/138920208786241243","article-title":"Genetics and molecular biology of tuberous sclerosis complex","volume":"9","author":"Napolioni","year":"2008","journal-title":"Current Genomics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0220|cit220","unstructured":"National Institute of Neurological Disorders and Stroke (NINDS) Tuberous sclerosis fact sheet www.ninds.nih.gov\/disorders\/tuberous_sclerosis\/detail_tuberous_sclerosis.htm"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0223|cit223","unstructured":"TUBEROUS SCLEROSIS 1; TSC1 Online Mendelian Inheritance in Man\u00ae - National Center for Biotechnology Information"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0224|cit224","unstructured":"TUBEROUS SCLEROSIS 2; TSC2 Online Mendelian Inheritance in Man\u00ae - National Center for Biotechnology Information"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0226|cit226","doi-asserted-by":"crossref","unstructured":"Overwater IE Rietman AB Elgersma Y de Wit MC Treatment of intractable epilepsy in tuberous sclerosis complex with everolimus is not yet evidence-based Annals of Neurology 2014 75 1 163 4 24243580","DOI":"10.1002\/ana.24047"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncb840","article-title":"Akt regulates growth by directly phosphorylating Tsc2","volume":"4","author":"Potter","year":"2002","journal-title":"Nature Cell Biology"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"Journal of Child Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011272.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/088307389901400610","article-title":"Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association","volume":"14","author":"Roach","year":"1999","journal-title":"Journal of Child Neurology"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00726-004-0119-z","article-title":"Proteins interacting with the tuberous sclerosis gene products","volume":"27","author":"Rosner","year":"2004","journal-title":"Amino Acids"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0231|cit231","unstructured":"Rapamune (Sirolimus) www.rxlist.com\/rapamune-drug.htm"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0232|cit232","unstructured":"Torisel (Temsirolimus) www.rxlist.com\/torisel-drug.htm"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0233|cit233","unstructured":"Cunha JP Afinitor (Everolimus) www.rxlist.com\/afinitor-drug.htm"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0234|cit234","unstructured":"SAS\u00ae SAS Institute Inc SAS Institute Inc 2013"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0235|cit235","doi-asserted-by":"crossref","unstructured":"Sasongko TH Ismail NF Nik Mohd Ariff NA Zabidi-Hussin ZA Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex-associated tumors: a systematic review on non-randomized studies using meta-analysis www.ojrd.com\/content\/10\/1\/95","DOI":"10.1186\/s13023-015-0317-7"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0236|cit236","first-page":"753","article-title":"Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat","volume":"20","author":"Sattler","year":"1992","journal-title":"Drug Metabolism & Disposition"},{"issue":"12","key":"10.1002\/14651858.CD011272.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-154-12-201106210-00008","article-title":"Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences","volume":"154","author":"Seibert","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011272.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ana.21342","article-title":"Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complexcortical tubers","volume":"63","author":"Talos","year":"2008","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0240|cit240","unstructured":"Tanzi MG Juice interactions: What patients need to know www.pharmacist.com\/juice-interactions-what-patients-need-know"},{"issue":"15","key":"10.1002\/14651858.CD011272.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Current Biology"},{"issue":"5","key":"10.1002\/14651858.CD011272.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1542\/peds.2010-2910","article-title":"Regression of a cardiac rhabdomyoma in a patient receiving everolimus","volume":"127","author":"Tiberio","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD011272.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D36TB7N61M","article-title":"Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response","volume":"18","author":"Truchuelo","year":"2012","journal-title":"Dermatology Online Journal"},{"issue":"11","key":"10.1002\/14651858.CD011272.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"e1005637","DOI":"10.1371\/journal.pgen.1005637","article-title":"Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing","volume":"11","author":"Tyburczy","year":"2015","journal-title":"PLoS Genetics"},{"issue":"5327","key":"10.1002\/14651858.CD011272.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"Slegtenhorst","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jmg.36.4.285","article-title":"Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation","volume":"36","author":"Slegtenhorst","year":"1999","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1634\/theoncologist.2013-0355","article-title":"Treatment-related mortality with everolimus in cancer patients","volume":"19","author":"Wesolowski","year":"2014","journal-title":"Oncologist"},{"issue":"33","key":"10.1002\/14651858.CD011272.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"11441","DOI":"10.1523\/JNEUROSCI.1283-12.2012","article-title":"Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission","volume":"32","author":"Weston","year":"2012","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD011272.pub3-BIB0249|cit249","first-page":"129","article-title":"Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report","volume":"45","author":"Wiemer-Kruel","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jneumeth.2015.04.007","article-title":"Genetic animal models of malformations of cortical development and epilepsy","volume":"260","author":"Wong","year":"2016","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1002\/14651858.CD011272.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy","volume":"2","author":"Yuan","year":"2009","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011272.pub3-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mousemodel of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD011272.pub3-BIB0253|cit253","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011272","article-title":"Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex","author":"Sasongko","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011272.pub3-BIB0254|cit254","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011272.pub2","article-title":"Rapamycin and rapalogs for tuberous sclerosis complex","author":"Sasongko","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:39:08Z","timestamp":1728049148000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011272.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":254,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011272.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}